Celgene News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

11.06.14	Celgene: Oral OTEZLA Shows Long-Term Benefits For Active Psoriatic Arthritis (RTTNews)
22.05.14	Celgene Promotes Mark Alles To President, COO; Names Peter Kellogg CFO (RTTNews)
06.05.14	Celgene Corporation -- Moody's rates Celgene's new notes Baa2; positive outlook (Moodys)
24.04.14	Celgene Q1 Adj. Profit Tops View, Backs 2014 View - Quick Facts (RTTNews)
03.04.14	Moody's: Pharmaceutical companies to benefit from new blood cancer drugs (Moodys)
21.03.14	FDA Approve Celgene's OTEZLA For Treatment Of Psoriatic Arthritis (RTTNews)
20.03.14	Celgene fördert Forschung und Patienteninitiativen zum Thema Bauchspeicheldrüsenkrebs in ganz Europa (Businesswire)
19.03.14	Celgene Reiterates Commitment to Improving Pancreatic Cancer Care in Europe, Through Significant Research and Patient Support Initiatives (Businesswire)
18.03.14	ATEC Sees Growth, FPRX Gets High-Five, RNA Walks The Talk, RPRX On The Move (RTTNews)
11.02.14	Celgene: Health Canada Approves Pomalyst For Patients With Multiple Myeloma (RTTNews)
30.01.14	Celgene Q4 Adj. Profit Misses Estimates, But Revenues Top; Backs 2014 View (RTTNews)
13.01.14	Celgene Lifts FY13 Outlook - Update (RTTNews)
13.01.14	Celgene Issues Q4 Earnings Outlook; Lifts FY13 Adj. EPS Outlook - Quick Facts (RTTNews)
08.01.14	Moody's: Healthcare Quarterly Looks at Key Developments for the Industry in 2014 (Moodys)
08.01.14	ABRAXANE® plus Gemcitabin erhält europäische Marktzulassung zur Erstlinienbehandlung von Patienten mit metastasierendem Bauchspeicheldrüsenkrebs (Businesswire)
08.01.14	CGEN Plans Busy Year, CytoDyn Gets Going, OREX Gets FDA Date, DRRX On A High (RTTNews)
07.01.14	Celgene: EC OKs Abraxane Plus Gemcitabine For Metastatic Pancreatic Cancer (RTTNews)
07.01.14	ABRAXANE® Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer (Businesswire)
18.12.13	Acceleron To Receive $7 Mln Milestone Payment From Celgene - Quick Facts (RTTNews)
17.12.13	Amgen Reports Positive Top-Line Results From Phase3 MENDEL-2 Trial Of Evolocumab (RTTNews)
11.12.13	Agios Pharma And Celgene Extend Cancer Metabolism Collaboration - Quick Facts (RTTNews)
08.12.13	First Analysis Of Extended Dosing With Celgene's CC-486 Presented At ASH (RTTNews)
03.12.13	OncoMed, Celgene To Jointly Advance Multiple Anti-Cancer Stem Cell Therapeutics (RTTNews)
25.11.13	AMGN, GSK Get FDA Nod, CLDX Walks The Talk, OREX Awaits Light, CELG On A High (RTTNews)
22.11.13	Celgene: ABRAXANE In Combination With Gemcitabine Gets Positive CHMP Opinion (RTTNews)
22.11.13	Celgene Receives Positive CHMP Opinion for ABRAXANE® in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer (Businesswire)
22.11.13	Celgene erhält positive CHMP-Stellungnahme für ABRAXANE® in Kombination mit Gemcitabin zur Behandlung von Patienten mit metastasiertem Pankreaskarzinom (Businesswire)
19.11.13	Celgene Invests $6.0 Mln In Alliqua - Quick Facts (RTTNews)
07.11.13	Celgene Reports Data From Phase III Study Of REVLIMID (RTTNews)
28.10.13	Celgene Int'l Sàrl Reports Results Of 3 Long-term PhaseIII Studies Of Apremilast (RTTNews)
24.10.13	Celgene Q3 Results Top Estimates; Boosts 2013 Outlook (RTTNews)
24.10.13	Celgene Q3 Profit Falls, Adj. EPS Tops Estimates; Lifts FY Adj. Profit View (RTTNews)
22.10.13	Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics (PR Newswire)
14.10.13	Trial Updates and Public Offering - Research Report on Gilead, Celgene, Ariad, Puma Biotechnology, and Dyax (PR Newswire)
09.10.13	Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. (PR Newswire)
04.10.13	Conference Calls, Philanthropic Activities, Clinical Trial Data, and Regulatory Approvals - Research Report on Celgene, UnitedHealth, Biogen Idec, WellPoint, and Medtronic (PR Newswire)
03.10.13	Oral verabreichtes Apremilast bewirkte signifikante Verbesserung von Nagel- und Kopfhautpsoriasis sowie gesundheitsbezogener Lebensqualität in Phase-III-Studie ESTEEM 1 (Businesswire)
03.10.13	Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study (Businesswire)
02.10.13	Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus (PR Newswire)
25.09.13	Data Presentations, FDA Approvals, Board Appointments, Updated Clinical Results and New Contracts - Research Report on Vertex, Celgene, NPS Pharmaceuticals, Cyclacel and BioCryst (PR Newswire)
24.09.13	Critical Alerts For Walter Energy, Celgene, GlaxoSmithKline, UnitedHealth Group, and Safeway Released By InvestorsObserver (PR Newswire)
12.09.13	FDA Approvals, Study Results, Multi-Year Collaborations, Data Presentations, and Supply Agreements - Research Report on Celgene, Amgen, Biogen Idec, Vertex, and Illumina (PR Newswire)
11.09.13	Nuvilex Eyes FDA Fast-Track After Abraxane Approved For Pancreatic Cancer (RTTNews)
06.09.13	Early Briefing and Review: Celgene Corp., Edwards Lifesciences Corp., Forest Laboratories Inc., and Peregrine Pharma Inc. (PR Newswire)
06.09.13	FDA OKs ABRAXANE Combined With Gemcitabine For Metastatic Pancreatic Cancer (RTTNews)
05.09.13	Celgene Provides Phase III Results On Pomalidomide Plus Low-dose Dexamethasone (RTTNews)
03.09.13	Pharmaceuticals Report Revolutionary Findings, Approved Treatments, Investor Conferences - Research Report on Celgene, Amgen, Biogen Idec, Regeneron, and Questcor (PR Newswire)
21.08.13	Healthy Outlook for Healthcare Supported by Trial Milestones, Approvals, Partnerships, and Commercialization - Research Report on Lilly, Celgene, Onyx, Amgen, and GSK (PR Newswire)
11.08.13	Morphosys erhöht Jahresprognosen - US-Kartellamt nickt Celgene-Deal ab (AWP)
10.08.13	MorphoSys Lifts FY13 View As MOR202 Alliance With Celgene Turns Effective (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

17:59		Freitagshandel in Europa: Euro STOXX 50 gibt zum Handelsende nach
17:59		Schwacher Wochentag in London: FTSE 100 beendet den Handel in der Verlustzone
17:59		Angespannte Stimmung in Frankfurt: LUS-DAX notiert zum Handelsende im Minus
17:59		Schwacher Handel: DAX liegt letztendlich im Minus
17:55		Bayer-Aktie profitiert: Niedrig dosiertes MRT-Kontrastmittel von Bayer besteht Phase-3-Studie - Zulassung für Kerendia in USA und China beantragt
16:24		Dezember 2024: Analysten sehen Potenzial bei Novartis-Aktie
15:58		Schwacher Handel: LUS-DAX in Rot
15:58		LSE-Handel FTSE 100 präsentiert sich nachmittags leichter